EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Jing, R., I. Scarfo, M. A. Najia, Lummertz da Rocha, A. Han, M. Sanborn, T. Bingham, et al. 2022. “EZH1 Repression Generates Mature IPSC-Derived CAR T Cells With Enhanced Antitumor Activity”. Cell Stem Cell 29: 1181-1196 e6.

Abstract

Human induced pluripotent stem cells (iPSCs) provide a potentially unlimited resource for cell therapies, but the derivation of mature cell types remains challenging. The histone methyltransferase EZH1 is a negative regulator of lymphoid potential during embryonic hematopoiesis. Here, we demonstrate that EZH1 repression facilitates in vitro differentiation and maturation of T cells from iPSCs. Coupling a stroma-free T cell differentiation system with EZH1-knockdown-mediated epigenetic reprogramming, we generated iPSC-derived T cells, termed EZ-T cells, which display a highly diverse T cell receptor (TCR) repertoire and mature molecular signatures similar to those of TCRalphabeta T cells from peripheral blood. Upon activation, EZ-T cells give rise to effector and memory T cell subsets. When transduced with chimeric antigen receptors (CARs), EZ-T cells exhibit potent antitumor activities in vitro and in xenograft models. Epigenetic remodeling via EZH1 repression allows efficient production of developmentally mature T cells from iPSCs for applications in adoptive cell therapy.

Last updated on 02/26/2024